INTERNATIONAL JOURNAL OF MICROBIAL SCIENCE

Publication Duration: Submission to first decision of acceptance – 16 days (two weeks), Acceptance to Publication: Maximum 8 Days (one week), Acceptance rate:10%, Article Processing Charges- Rs.3000/- (For Indian Authors), 38.70 Dollars (For others)

References

  1. Chumakov, K., Ehrenfeld, E., Wimmer, E., & Agol, V. I. (2007). Vaccination against polio should not be stopped.  Nature reviews. Microbiology, 5(12), 952–958. https://doi.org/10.1038/nrmicro1769
  2. Malvy, D., McElroy, A. K., de Clerck, H., Günther, S., & van Griensven, J. (2019). Ebola virus disease. Lancet (London, England), 393(10174),936–948. https://doi.org/10.1016/S0140-6736(18)33132-5
  3. Malvy, D., McElroy, A. K., de Clerck, H., Günther, S., & van Griensven, J. (2019). Ebola virus disease. Lancet (London, England), 393(10174),936–948. https://doi.org/10.1016/S0140-6736(18)33132-5
  4. Heininger, U., & Seward, J. F. (2006). Varicella. Lancet (London, England), 368(9544), 1365–1376. https://doi.org/10.1016/S0140-6736(06)69561-5
  5. A, K., S, C., RB, S., H, V., SS, S., & A, G. (2016). A REVIEW ON: HIV AIDS. Indian Journal of Pharmaceutical and Biological Research, 4(03), 69-73. https://doi.org/10.30750/ijpbr.4.3.9
  6. Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015). Polio vaccination: past, present and future. Future microbiology, 10(5),791–808. https://doi.org/10.2217/fmb.15.19
  7. Ogra, P. L., & Volovitz, B. (1987). Diagnosis and treatment of viral infections. Bulletin of the New York Academy of Medicine, 63(6), 475–483.
  8. Coffin, J. M. (1999). Molecular biology of HIV. In: The Evolution of HIV (Crandall K.A., ed.). pp. 3-40. Johns Hopkins University Press, Baltimore, MD.
  9. Hu, B., Zeng, L. P., Yang, X. L., Ge, X. Y., Zhang, W., Li, B., Xie, J. Z., Shen, X. R., Zhang, Y. Z., Wang, N., Luo, D. S., Zheng, X. S., Wang, M. N., Daszak, P., Wang, L. F., Cui, J., & Shi, Z. L. (2017). Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS pathogens, 13(11), e1006698. https://doi.org/10.1371/journal.ppat.1006698
  10. Dudas, G., Carvalho, L. M., Rambaut, A., & Bedford, T. (2018). MERS-CoV spillover at the camel-human interface. eLife, 7,e31257. https://doi.org/10.7554/eLife.31257
  11. Leopardi, S., Holmes, E. C., Gastaldelli, M., Tassoni, L., Priori, P., Scaravelli, D., Zamperin, G., & De Benedictis, P. (2018). Interplay between co-divergence and cross-species transmission in the evolutionary history of bat coronaviruses. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases,  58, 279–289. https://doi.org/10.1016/j.meegid.2018.01.012
  12. Wang, N., Li, S. Y., Yang, X. L., Huang, H. M., Zhang, Y. J., Guo, H., Luo, C. M., Miller, M., Zhu, G., Chmura, A. A., Hagan, E., Zhou, J. H., Zhang, Y. Z., Wang, L. F., Daszak, P., & Shi, Z. L. (2018). Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China. Virologica Sinica, 33(1),104–107. https://doi.org/10.1007/s12250-018-0012-7
  13. Dhakane, R.D., Shinde, A.H, Bhattacharjee, S.B., & Wagh, S.G. (2020). Can Coronaviridae Viruses Reappear with their Novel Variants in Upcoming Years? A Review. International Journal of Microbial Science, 1(1), 1-5.
  14. Takizawa, N., & Yamasaki, M. (2017). Current landscape and future prospects of antiviral drugs derived from microbial products. The Journal of antibiotics, 71(1), 45–52. Advance online publication. https://doi.org/10.1038/ja.2017.115
  15. Li, H., Wei, Q., Tan, A., & Wang, L. (2013). Epidemiological analysis of respiratory viral etiology for influenza-like illness during 2010 in Zhuhai, China. Virology journal, 10, 143. https://doi.org/10.1186/1743-422X-10-143
  16. Parveen, S., Sullender, W. M., Fowler, K., Lefkowitz, E. J., Kapoor, S. K., & Broor, S. (2006). Genetic variability in the G protein gene of group A and B respiratory syncytial viruses from India. Journal of clinical microbiology, 44(9), 3055–3064. https://doi.org/10.1128/JCM.00187-06
  17.  Williams, B. G., Gouws, E., Boschi-Pinto, C., Bryce, J., & Dye, C. (2002). Estimates of world-wide distribution of child
  18. deaths from acute respiratory infections. The Lancet. Infectious diseases,  2(1), 25–32. https://doi.org/10.1016/s1473-3099(01)00170-0
  19. Bharaj, P., Sullender, W. M., Kabra, S. K., Mani, K., Cherian, J., Tyagi, V., Chahar, H. S., Kaushik, S., Dar, L., & Broor, S. (2009). Respiratory viral infections detected by multiplex PCR among pediatric patients with lower respiratory tract infections seen at an urban hospital in Delhi from 2005 to 2007. Virology journal,  6, 89. https://doi.org/10.1186/1743-422X-6-89
  20. Malhotra, B., Swamy, M. A., Janardhan Reddy, P. V., & Gupta, M. L. (2016). Viruses causing severe acute respiratory infections (SARI) in children ≤5 years of age at a tertiary care hospital in Rajasthan, India. The Indian journal of medical research, 144(6),877–885. https://doi.org/10.4103/ijmr.IJMR_22_15
  21. World Health Organization (2013). Regional Office for Europe. Overview of sentinel systems for hospitalized severe acute respiratory infections (SARI) represented in the weekly Euro Flu surveillance bulletin (as of 10 February 2013). Available from: http://www.euro.who.int/__data/assets/pdf_file/0005/186863/Overview-of-SARI-Surveillance-Systemsfinal.pdf accessed on May 5, 2013.
  22. Pan American Health Organization (2009). Regional Office of the World Health Organization. Health Establishments Preparation for Unusual or Unexpected Cases or Clusters of Severe Acute Respiratory Infection (SARI). Available from: https://www.paho.org/hq/dmdocuments/2009/SARI%20English_Module_Final.pdf
  23. Zhang, C., Zhu, N., Xie, Z., Lu, R., He, B., Liu, C., Ma, X., & Tan, W. (2013). Viral etiology and clinical profiles of children with severe acute respiratory infections in China. PloS one, 8(8), e72606. https://doi.org/10.1371/journal.pone.0072606
  24. Hatem, A., Mohamed, S., Abu Elhassan, U. E., Ismael, E., Rizk, M. S., El-Kholy, A., & El-Harras, M. (2019). Clinical characteristics and outcomes of patients with severe acute respiratory infections (SARI): results from the Egyptian surveillance study 2010-2014. Multidisciplinary respiratory medicine, 14,11.                     https://doi.org/10.1186/s40248-019-0174-7
  25. Meerhoff, T. J., Simaku, A., Ulqinaku, D., Torosyan, L., Gribkova, N., Shimanovich, V., Chakhunashvili, G., Karseladze, I., Yesmagambetova, A., Kuatbayeva, A., Nurmatov, Z., Otorbaeva, D., Lupulescu, E., Popovici, O., Smorodintseva, E., Sominina, A., Holubka, O., Onyshchenko, O., Brown, C. S., & Gross, D. (2015). Surveillance for severe acute respiratory infections (SARI) in hospitals in the WHO European region – an exploratory analysis of risk factors for a severe outcome in influenza-positive SARI cases. BMC infectious diseases,  15, 1. https://doi.org/10.1186/s12879-014-0722-x 
  26. Bardsley-Elliot, A., & Noble, S. (1999). Oseltamivir. Drugs, 58(5),851–862. https://doi.org/10.2165/00003495-199958050-00007
  27. Lew, W., Chen, X., & Kim, C. U. (2000). Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Current medicinal chemistry, 7(6),663–672. https://doi.org/10.2174/0929867003374886
  28. Burger, R. A., Billingsley, J. L., Huffman, J. H., Bailey, K. W., Kim, C. U., & Sidwell, R. W. (2000). Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice. Immunopharmacology, 47(1),45– https://doi.org/10.1016/s0162-3109(99)00184-8
  29. Doucette, K. E., & Aoki, F. Y. (2001). Oseltamivir: a clinical and pharmacological perspective. Expert opinion on pharmacotherapy, 2(10),1671–1683. https://doi.org/10.1517/14656566.2.10.1671
  30. Ison, M. G., & Hayden, F. G. (2017). Antiviral Agents Against Respiratory Viruses. Infectious Diseases, 1318–1326.e2. https://doi.org/10.1016/B978-0-7020-6285-8.00154-4
  31. McClellan, K., & Perry, C. M. (2001). Oseltamivir: a review of its use in influenza. Drugs, 61(2), 263–283. https://doi.org/10.2165/00003495-200161020-00011
  32. He, G., Massarella, J., & Ward, P. (1999). Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clinical pharmacokinetics, 37(6), 471–484. https://doi.org/10.2165/00003088-199937060-00003
  33. Rayner, C. R., Bulik, C. C., Kamal, M. A., Reynolds, D. K., Toovey, S., Hammel, J. P., Smith, P. F., Bhavnani, S. M., Van Wart, S. A., Ambrose, P. G., & Forrest, A. (2013). Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Antimicrobial agents and chemotherapy, 57(8), 3478–3487. https://doi.org/10.1128/AAC.02440-12
  34. Loeffelholz, M., & Chonmaitree, T. (2010). Advances in diagnosis of respiratory virus infections. International journal of microbiology, 2010, 126049. https://doi.org/10.1155/2010/126049
  35. McNicholl, I. R., & McNicholl, J. J. (2001). Neuraminidase inhibitors: zanamivir and oseltamivir. The Annals of pharmacotherapy, 35(1),57–70. https://doi.org/10.1345/aph.10118
  36. Sharma Prince, Roy Ram, Chaudhary, Anurag. (2010). Neuraminidase inhibitors: Oseltamivir, Peramivir, Synthesis and Profile. Journal of Pharmacy Research, 3.
  37. Cooper, N. J., Sutton, A. J., Abrams, K. R., Wailoo, A., Turner, D., & Nicholson, K. G. (2003). Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ (Clinical research ed.), 326(7401), 1235. https://doi.org/10.1136/bmj.326.7401.1235
  38. Oo, C., Barrett, J., Hill, G., Mann, J., Dorr, A., Dutkowski, R., & Ward, P. (2001). Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatric drugs, 3(3), 229–236. https://doi.org/10.2165/00128072-200103030-00005
  39. Kamali, A., & Holodniy, M. (2013). Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infection and drug resistance, 6, 187–198. https://doi.org/10.2147/IDR.S36601
  40. Welliver, R., Monto, A. S., Carewicz, O., Schatteman, E., Hassman, M., Hedrick, J., Jackson, H. C., Huson, L., Ward, P., Oxford, J. S., & Oseltamivir Post Exposure Prophylaxis Investigator Group (2001). Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.  JAMA,  285(6), 748–754. https://doi.org/10.1001/jama.285.6.748
  41. Ison, M. G., Szakaly, P., Shapira, M. Y., Kriván, G., Nist, A., & Dutkowski, R. (2012). Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antiviral therapy, 17(6), 955–964. https://doi.org/10.3851/IMP2192
  42. Hayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills, R. G., Ward, P., & Straus, S. E. (1999). Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA, 282(13),1240–1246. https://doi.org/10.1001/jama.282.13.1240
  43. Carr, J., Ives, J., Kelly, L., Lambkin, R., Oxford, J., Mendel, D., Tai, L., & Roberts, N. (2002). Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral research,  54(2), 79–88. https://doi.org/10.1016/s0166-3542(01)00215-7
  44. Baz, M., Abed, Y., Papenburg, J., Bouhy, X., Hamelin, M. E., & Boivin, G. (2009). Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. The New England journal of medicine,  361(23), 2296–2297. https://doi.org/10.1056/NEJMc0910060
  45. Fiore, A. E., Fry, A., Shay, D., Gubareva, L., Bresee, J. S., Uyeki, T. M., & Centers for Disease Control and Prevention (CDC) (2011). Antiviral agents for the treatment and chemoprophylaxis of influenza — recommendations of the Advisory Committee on Immunization Practices (ACIP).  Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports, 60(1), 1–24.
  46. Hsu, J., Santesso, N., Mustafa, R., Brozek, J., Chen, Y. L., Hopkins, J. P., Cheung, A., Hovhannisyan, G., Ivanova, L., Flottorp, S. A., Saeterdal, I., Wong, A. D., Tian, J., Uyeki, T. M., Akl, E. A., Alonso-Coello, P., Smaill, F., & Schünemann, H. J. (2012). Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Annals of  internal medicine,  156(7), 512–524. https://doi.org/10.7326/0003-4819-156-7-2012040300041
  47. Kamal, M. A., Acosta, E. P., Kimberlin, D. W., Gibiansky, L., Jester, P., Niranjan, V., Rath, B., Clinch, B., Sánchez, P. J., Ampofo, K., Whitley, R., & Rayner, C. R. (2014). The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach. Clinical pharmacology and therapeutics, 96(3), 380–389. https://doi.org/10.1038/clpt.2014.120
  48. Kimberlin, D. W., Acosta, E. P., Prichard, M. N., Sánchez, P. J., Ampofo, K., Lang, D., Ashouri, N., Vanchiere, J. A., Abzug, M. J., Abughali, N., Caserta, M. T., Englund, J. A., Sood, S. K., Spigarelli, M. G., Bradley, J. S., Lew, J., Michaels, M. G., Wan, W., Cloud, G., Jester, P., … National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (2013). Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. The Journal of infectious diseases, 207(5), 709–720. https://doi.org/10.1093/infdis/jis765
  49. Whitley, R. J., Hayden, F. G., Reisinger, K. S., Young, N., Dutkowski, R., Ipe, D., Mills, R. G., & Ward, P. (2001). Oral oseltamivir treatment of influenza in children. The Pediatric infectious disease journal, 20(2), 127–133. https://doi.org/10.1097/00006454-200102000-00002
  50. Piedra, P. A., Schulman, K. L., & Blumentals, W. A. (2009). Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics, 124(1), 170–178. https://doi.org/10.1542/peds.2008-0977
  51. Kumar, D., Michaels, M. G., Morris, M. I., Green, M., Avery, R. K., Liu, C., Danziger-Isakov, L., Stosor, V., Estabrook, M., Gantt, S., Marr, K. A., Martin, S., Silveira, F. P., Razonable, R. R., Allen, U. D., Levi, M. E., Lyon, G. M., Bell, L. E., Huprikar, S., Patel, G., … American Society of Transplantation H1N1 Collaborative Study Group (2010). Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. The Lancet. Infectious diseases,  10(8), 521–526. https://doi.org/10.1016/S1473-3099(10)70133-X
  52. Reid, G., Huprikar, S., Patel, G., Razonable, R. R., Mossad, S., Levi, M., Gregg, K., Shoham, S., Humar, A., Adams, W., & Kumar, D. (2013). A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients. Transplant infectious disease: an official journal of the Transplantation Society, 15(5), 487–492. https://doi.org/10.1111/tid.12116
  53. Lee, N., & Ison, M. G. (2012). Diagnosis, management and outcomes of adults hospitalized with influenza. Antiviral therapy, 17(1 Pt B), 143–157. https://doi.org/10.3851/IMP2059
  54. Lee, N., & Ison, M. G. (2012). Editorial commentary. “Late” treatment with neuraminidase inhibitors for severely ill patients with influenza: better late than never?. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 55(9), 1205–1208. https://doi.org/10.1093/cid/cis642
  55. Louie, J. K., Yang, S., Acosta, M., Yen, C., Samuel, M. C., Schechter, R., Guevara, H., & Uyeki, T. M. (2012). Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 55(9),1198–1204. https://doi.org/10.1093/cid/cis636
  56. Muthuri, S. G., Venkatesan, S., Myles, P. R., Leonardi-Bee, J., Al Khuwaitir, T. S., Al Mamun, A., Anovadiya, A. P., Azziz-Baumgartner, E., Báez, C., Bassetti, M., Beovic, B., Bertisch, B., Bonmarin, I., Booy, R., Borja-Aburto, V. H., Burgmann, H., Cao, B., Carratala, J., Denholm, J. T., Dominguez, S. R., … Nguyen-Van-Tam, J. S. (2014). Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. The Lancet. Respiratory medicine,  2(5), 395–404. https://doi.org/10.1016/S2213-2600(14)70041-4
  57. Beau, A. B., Hurault-Delarue, C., Vial, T., Montastruc, J. L., Damase-Michel, C., & Lacroix, I. (2014). Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database. BJOG : an international journal of obstetrics and gynaecology, 121(7),895–900. https://doi.org/10.1111/1471-0528.12617
  58. Wollenhaupt, M., Chandrasekaran, A., & Tomianovic, D. (2014). The safety of oseltamivir in pregnancy: an updated review of post-marketing data. Pharmacoepidemiology and drug safety,  23(10), 1035–1042. https://doi.org/10.1002/pds.3673
  59. Saito, S., Minakami, H., Nakai, A., Unno, N., Kubo, T., & Yoshimura, Y. (2013). Outcomes of infants exposed to oseltamivir or zanamivir in utero during pandemic (H1N1) 2009. American journal of obstetrics and gynecology, 209(2), 130.e1–130.e1309. Acosta, E. P., Jester, P., Gal, P., Wimmer, J., Wade, J., Whitley, R. J., Kimberlin, D. W., & National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (2010). Oseltamivir dosing for influenza infection in premature neonates. The Journal of infectious diseases, 202(4), 563–566. https://doi.org/10.1086/654930
  60. Fry, A. M., Goswami, D., Nahar, K., Sharmin, A. T., Rahman, M., Gubareva, L., Azim, T., Bresee, J., Luby, S. P., & Brooks, W. A. (2014). Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. The Lancet. Infectious diseases,  14(2), 109–118. https://doi.org/10.1016/S1473-3099(13)70267-6
  61. Kaiser, L., Wat, C., Mills, T., Mahoney, P., Ward, P., & Hayden, F. (2003). Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Archives of internal medicine, 163(14), 1667–1672. https://doi.org/10.1001/archinte.163.14.1667 
  62. Greer, L. G., Leff, R. D., Rogers, V. L., Roberts, S. W., McCracken, G. H., Jr, Wendel, G. D., Jr, & Sheffield, J. S. (2011). Pharmacokinetics of oseltamivir according to trimester of pregnancy. American journal of obstetrics and gynecology, 204(6 Suppl 1), S89–S93. https://doi.org/10.1016/j.ajog.2011.03.005
  63. Greer, L. G., Leff, R. D., Rogers, V. L., Roberts, S. W., McCracken, G. H., Jr, Wendel, G. D., Jr, & Sheffield, J. S. (2011). Pharmacokinetics of oseltamivir according to trimester of pregnancy. American journal of obstetrics and gynecology, 204(6 Suppl 1), S89–S93. https://doi.org/10.1016/j.ajog.2011.03.005
  64. Lee, N., Hui, D. S., Zuo, Z., Ngai, K. L., Lui, G. C., Wo, S. K., Tam, W. W., Chan, M. C., Wong, B. C., Wong, R. Y., Choi, K. W., Sin, W. W., Lee, E. L., Tomlinson, B., Hayden, F. G., & Chan, P. K. (2013). A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57(11),1511–1519. https://doi.org/10.1093/cid/cit597
  65. South East Asia Infectious Disease Clinical Research Network (2013). Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ (Clinical research ed.), 346, f3039. https://doi.org/10.1136/bmj.f3039
  66. Kumar A. (2013). Viral Clearance with Standard or Triple Dose Oseltamivir Therapy in Critically Ill Patients with Pandemic (H1N1) 2009 Influenza. ICAAC 2013. Denver, Colorado, 2013:B-1470.
  67. FDA–Food & Drug Administration, FDA Approves Tamiflu for Prevention of Influenza in Children Under Age 12. Available at: http://test.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm1045252.htm
  68. Beigel, J., & Bray, M. (2008). Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral research, 78(1),91–102. https://doi.org/10.1016/j.antiviral.2008.01.003
  69. Beigi, R. H., Han, K., Venkataramanan, R., Hankins, G. D., Clark, S., Hebert, M. F., Easterling, T., Zajicek, A., Ren, Z., Mattison, D. R., Caritis, S. N., & Obstetric-Fetal Pharmacology Research Units Network (2011). Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. American journal of obstetrics and gynecology, 204(6 Suppl 1), S84–S88. https://doi.org/10.1016/j.ajog.2011.03.002
  70. Toovey, S., Prinssen, E. P., Rayner, C. R., Thakrar, B. T., Dutkowski, R., Koerner, A., Chu, T., Sirzen-Zelenskaya, A., Britschgi, M., Bansod, S., & Donner, B. (2012). Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Advances in therapy, 29(10), 826–848. https://doi.org/10.1007/s12325-012-0050-8
  71. Hoffman KB, Demakas A, Erdman CB, Dimbil M, Doraiswamy PM. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ. 2013 Jul 23;347:f4656. doi: 10.1136/bmj.f4656  PMID: 23881998
  72. Lam, H., Jeffery, J., Sitar, D. S., & Aoki, F. Y. (2011). Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. Therapeutic drug monitoring, 33(6), 699–704. https://doi.org/10.1097/FTD.0b013e3182399448
  73. Hill, G., Cihlar, T., Oo, C., Ho, E. S., Prior, K., Wiltshire, H., Barrett, J., Liu, B., & Ward, P. (2002). The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug metabolism and disposition: the biological fate of chemicals, 30(1), 13–19. https://doi.org/10.1124/dmd.30.1.13
  74. Schirmer, P., & Holodniy, M. (2009). Oseltamivir for treatment and prophylaxis of influenza infection. Expert opinion on drug safety, 8(3), 357–371. https://doi.org/10.1517/14740330902840519
  75. McKimm-Breschkin, J., Trivedi, T., Hampson, A., Hay, A., Klimov, A., Tashiro, M., Hayden, F., & Zambon, M. (2003). Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrobial agents and chemotherapy, 47(7), 2264–2272.                          https://doi.org/10.1128/aac.47.7.2264-2272.2003
  76. Lew, W., Chen, X., & Kim, C. U. (2000). Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Current medicinal chemistry, 7(6),663–672. https://doi.org/10.2174/0929867003374886
  77. Tai, C. Y., Escarpe, P. A., Sidwell, R. W., Williams, M. A., Lew, W., Wu, H., Kim, C. U., & Mendel, D. B. (1998). Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrobial agents and chemotherapy, 42(12), 3234–3241. https://doi.org/10.1128/AAC.42.12.3234
  78. Ives, J. A., Carr, J. A., Mendel, D. B., Tai, C. Y., Lambkin, R., Kelly, L., Oxford, J. S., Hayden, F. G., & Roberts, N. A. (2002). The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.  Antiviral research,  55(2), 307–317. https://doi.org/10.1016/s0166-3542(02)00053-0
  79. Yen, H. L., Herlocher, L. M., Hoffmann, E., Matrosovich, M. N., Monto, A. S., Webster, R. G., & Govorkova, E. A. (2005). Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrobial agents and chemotherapy, 49(10),4075–4084. https://doi.org/10.1128/AAC.49.10.4075-4084.2005 influenza (flu) health professionals antiviral drugs. c2015 [cited 2016 September 25]. Available from: http://www.cdc.gov/flu/professionals/antivirals/antiviral-drug-resistance.htm
  80.  Centres for Disease Control and Prevention (CDC) [Internet]. Antiviral drug resistance among influenza viruses. Seasonal influenza (flu) health professionals antiviral drugs. c2015 [cited 2016 September 25]. Available from: http://www.cdc.gov/flu/professionals/antivirals/antiviral-drug-resistance.htm
  81. Le, Q. M., Wertheim, H. F., Tran, N. D., van Doorn, H. R., Nguyen, T. H., Horby, P., & Vietnam H1N1 Investigation Team (2010). A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. The New England journal of medicine, 362(1),86–87. https://doi.org/10.1056/NEJMc0910448
  82. Centers for Disease Control and Prevention (CDC) (2009). Oseltamivir resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009. MMWR, 58(32):893.
  83. Centers for Disease Control and Prevention (CDC) (2009). Oseltamivir resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-north Carolina-2009. MMWR, 58(35):969–972.
  84. Inoue M, Barkham T, Leo YS, Chan KP, Chow A, Wong CW, Tze Chuen Lee R, Maurer-Stroh S, Lin R, Lin C. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. Emerg Infect Dis. 2010 Oct; 16(10):1633-6. doi: 10.3201/eid1610.100688  PMID: 20875299; PMCID: PMC3294403.
  85. Le, Q. M., Wertheim, H. F., Tran, N. D., van Doorn, H. R., Nguyen, T. H., Horby, P., & Vietnam H1N1 Investigation Team (2010). A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. The New England journal of medicine, 362(1),86–87. https://doi.org/10.1056/NEJMc0910448
  86. Hatakeyama, S., Sugaya, N., Ito, M., Yamazaki, M., Ichikawa, M., Kimura, K., Kiso, M., Shimizu, H., Kawakami, C., Koike, K., Mitamura, K., & Kawaoka, Y. (2007). Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA, 297(13),1435–1442. https://doi.org/10.1001/jama.297.13.1435
  87. Gubareva, L. V., Matrosovich, M. N., Brenner, M. K., Bethell, R. C., & Webster, R. G. (1998). Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. The Journal of infectious diseases, 178(5), 1257–1262. https://doi.org/10.1086/314440
  88. Ison, M. G., Gubareva, L. V., Atmar, R. L., Treanor, J., & Hayden, F. G. (2006). Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. The Journal of infectious diseases, 193(6), 760–764. https://doi.org/10.1086/500465
  89. Centers for Disease Control and Prevention (CDC) (2009). Oseltamivir resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-north Carolina-2009. MMWR, 58(35):969–972.
  90. Stephenson, I., Democratis, J., Lackenby, A., McNally, T., Smith, J., Pareek, M., Ellis, J., Bermingham, A., Nicholson, K., & Zambon, M. (2009). Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 48(4), 389–396. https://doi.org/10.1086/596311
  91. Fica, A., Sotomayor, V., Fasce, R., Dabanch, J., Soto, A., Charpentier, P., Guerrero, G., Olivares, F., Triantafilo, V., Omeiri, N. E., & Gaínza-Lein, M. (2019). Severe acute respiratory infections (SARI) from influenza in adult patients in Chile: the experience of a sentinel hospital. Revista panamericana de salud publica = Pan American journal of public health, 43, e1. https://doi.org/10.26633/RPSP.2019.1
  92. Pretorius, M. A., Tempia, S., Walaza, S., Cohen, A. L., Moyes, J., Variava, E., Dawood, H., Seleka, M., Hellferscee, O., Treurnicht, F., Cohen, C., & Venter, M. (2016). The role of influenza, RSV and other common respiratory viruses in severe acute respiratory infections and influenza-like illness in a population with a high HIV sero-prevalence, South Africa 2012-2015. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 75,21–26. https://doi.org/10.1016/j.jcv.2015.12.004

Copyright © All rights reserved | Blogus by Themeansar.